What Is a PDUFA Date?

What Does PDUFA Stand For?

PDUFA stands for the Prescription Drug User Fee Act. Passed in 1992, this legislation allows the FDA to collect fees from pharmaceutical companies that submit drug applications. In exchange, the FDA commits to reviewing those applications within a specific timeframe. That deadline is the PDUFA date.

When a biotech company submits a New Drug Application (NDA) or Biologics License Application (BLA), the FDA assigns a target action date — typically 10 months after submission for standard review or 6 months for priority review. This is what traders call the PDUFA date. The FDA meets its PDUFA goals more than 90% of the time.

Why PDUFA Dates Matter for Biotech Stocks

PDUFA dates are among the most significant binary events in biotech investing. On or before this date, the FDA will issue one of three outcomes: approval, a Complete Response Letter rejecting the application, or an extension requesting additional information.

Approvals can send a stock up 30–100% or more, particularly for small-cap companies with a single drug in their pipeline. CRLs can trigger crashes of 50–80% overnight. Even an approval can cause the stock to drop if the market had already priced it in. This is why experienced biotech traders track PDUFA dates religiously.

How to Find Upcoming PDUFA Dates

PDUFA dates are publicly available through several sources. The FDA publishes upcoming action dates on its website, though the format is not trader-friendly. Bloomberg Terminal includes PDUFA calendars but costs upward of $20,000 per year.

The challenge is not finding the dates — it's understanding which ones matter. A PDUFA date for a large-cap pharma company adding a minor label expansion is a very different event than a PDUFA date for a micro-cap biotech whose entire value depends on a single drug approval. This is exactly the problem algorithmic catalyst ranking solves.

PDUFA Date vs. Advisory Committee Meeting

An AdCom meeting is a panel of outside experts who review the drug's data and vote on whether to recommend approval. The FDA follows the committee's recommendation roughly 75–80% of the time. AdCom meetings typically happen 2–3 months before the PDUFA date.

A PDUFA date after a favorable AdCom may produce a smaller move because the approval is partially priced in. A PDUFA date without a preceding AdCom carries more uncertainty and often produces larger moves.

Common Mistakes Traders Make with PDUFA Dates

The most dangerous mistake is assuming a positive FDA decision always means a positive stock move. It does not. Approvals can come with label restrictions, REMS requirements, or black box warnings that limit commercial potential.

Another common mistake is holding a large position through a PDUFA date without understanding the risk. A stock can gap 50%+ in either direction overnight. Options pricing often makes hedging prohibitively expensive.

Related Articles